Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
ZacksAMRX stock gains 29.3% in a month due to the FDA’s approval of Parkinson’s Disease drug, Crexont.
AMRX stock gains 29.3% in a month due to the FDA’s approval of Parkinson’s Disease drug, Crexont.